PMID- 15468069 OWN - NLM STAT- MEDLINE DCOM- 20050601 LR - 20091119 IS - 0021-9541 (Print) IS - 0021-9541 (Linking) VI - 203 IP - 2 DP - 2005 May TI - TGF-beta-induced expression of tissue inhibitor of metalloproteinases-3 gene in chondrocytes is mediated by extracellular signal-regulated kinase pathway and Sp1 transcription factor. PG - 345-52 AB - Transforming growth factor (TGF-beta1) is a potent inducer of chondrogenesis and stimulant of cartilage extracellular matrix (ECM) synthesis. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is located in ECM and is the major inhibitor of matrix metalloproteinases (MMPs) and aggrecanase, the principal enzymes implicated in collagen and aggrecan degradation in arthritis. We investigated the role of extracellular-signal-regulated kinase (ERK)-mitogen-activated protein kinases (MAPK) and Sp1 transcription factor in TGF-beta-induced TIMP-3 gene in chondrocytes and chondrosarcoma cells. TGF-beta time-dependently induced a sustained phosphorylation of ERK-MAPKs in primary human or bovine chondrocytes. Inhibitors of this pathway, PD98059 and U0126, downregulated TGF-beta-induced expression of TIMP-3 RNA and protein. Since the ERKs can phosphorylate Sp1, and the promoter of human TIMP-3 gene contains four Sp1-binding sites, we investigated whether Sp1 is a downstream target of this pathway. Mithramycin and WP631, the agents that prevent binding of Sp1 to its consensus site, downregulated TGF-beta-inducible TIMP-3 expression. Indeed, mithramycin blocked TGF-beta-stimulated Sp1 binding activity. Transfection of cytomegalovirus (CMV) promoter-Sp1 plasmid increased TIMP-3 promoter (-940 to +376)-driven luciferase activity. Depletion of Sp1 by transfection of an antisense phosphorothioate oligonucleotide suppressed TGF-beta-induced TIMP-3 protein expression, while its sense homolog had no effect. These results suggest that activation of ERK-MAPK pathway and Sp1 transcription factor play a pivotal role in the induction of TIMP-3 by TGF-beta in chondrocytes. CI - Copyright 2004 Wiley-Liss, Inc. FAU - Qureshi, Hamid Yaqoob AU - Qureshi HY AD - Department of Medicine and Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM), Montreal, Quebec, Canada. FAU - Sylvester, Judith AU - Sylvester J FAU - El Mabrouk, Mohammed AU - El Mabrouk M FAU - Zafarullah, Muhammad AU - Zafarullah M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Cell Physiol JT - Journal of cellular physiology JID - 0050222 RN - 0 (Enzyme Inhibitors) RN - 0 (Oligodeoxyribonucleotides, Antisense) RN - 0 (Protein Synthesis Inhibitors) RN - 0 (Sp1 Transcription Factor) RN - 0 (Tissue Inhibitor of Metalloproteinase-3) RN - 0 (Transforming Growth Factor beta) RN - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases) SB - IM MH - Animals MH - Binding Sites/drug effects/physiology MH - Cartilage/cytology/drug effects/*metabolism MH - Cattle MH - Cells, Cultured MH - Chondrocytes/drug effects/*metabolism MH - Chondrogenesis/drug effects/physiology MH - Enzyme Inhibitors/pharmacology MH - Extracellular Matrix/metabolism MH - Extracellular Signal-Regulated MAP Kinases/*metabolism MH - Gene Expression Regulation/genetics MH - Gene Expression Regulation, Enzymologic/drug effects/physiology MH - Genetic Vectors/genetics MH - Humans MH - Oligodeoxyribonucleotides, Antisense/genetics MH - Phosphorylation/drug effects MH - Promoter Regions, Genetic/genetics MH - Protein Synthesis Inhibitors/pharmacology MH - Regeneration/drug effects/physiology MH - Sp1 Transcription Factor/*metabolism MH - Tissue Inhibitor of Metalloproteinase-3/*metabolism MH - Transforming Growth Factor beta/*metabolism/pharmacology MH - Tumor Cells, Cultured EDAT- 2004/10/07 09:00 MHDA- 2005/06/02 09:00 CRDT- 2004/10/07 09:00 PHST- 2004/10/07 09:00 [pubmed] PHST- 2005/06/02 09:00 [medline] PHST- 2004/10/07 09:00 [entrez] AID - 10.1002/jcp.20228 [doi] PST - ppublish SO - J Cell Physiol. 2005 May;203(2):345-52. doi: 10.1002/jcp.20228.